Study | Drugs | Topic | Intervention | Condition |
---|---|---|---|---|
NCT03310034 | Trp, NA, NAM | To evaluate the effect of NAD + precursors on mitochondrial function, energy metabolism and physical function | Adults aged 65 to 75 years will take 207.5 mg niacin equivalents or placebo daily for 31 days | Aging Mitochondrial function |
NCT03818802 | NR | To evaluate the effect of NR in bone, skeletal muscle and metabolic functions in aging | Elderly female volunteers aged 65 to 80 years will take 1000 mg of NR or placebo daily for 6 months | Aging |
NCT05483465 | NR | To evaluate the effect of NR supplementation on brain vascular health in aging | Adults aged 65 to 80 years in the community will take 1000 mg of NR or placebo daily for 8 weeks | Aging |
NCT04907110 | NR | To evaluate the effects of exercise training combined with NR supplementation on metabolic health in older individuals | Adults aged 65 to 80 years with a BMI between 25–35 kg/m2 will take 1000 mg of NR or placebo daily for 40 days | Overweight and obesity Aging Type 2 diabetes |
NCT02921659 | NR | To evaluate the efficacy of NR for improving physiological function | For adults aged 55 to 80 years, a placebo crossover will precede a 6-week intervention with 500 mg of NR twice daily | Aging |
NCT03821623 | NR | To evaluate the efficacy of NR for targeting elevated systolic blood pressure and arterial stiffness | Healthy adults older than 50 years will take 250 or 1000 mg NR or placebo daily for 3 months | Aging |
NCT04040959 | NR | To evaluate the efficacy of NR for targeting arterial stiffness and elevated systolic blood pressure | Moderate to severe chronic kidney disease patients aged 35 to 80 years will take 500 mg NR or placebo daily for 3 months | Vascular diseases Kidney disease Blood pressure Oxidative stress |
NCT04110028 | NR | To investigate whether NR can shorten the recovery phase and improve outcome after acute illness | Patients with acute illness over 18 years old will take NR or placebo 50,500,1000 and 2000 mg daily, and each dose lasts for 90 days | Inflammation Acute illness |
NCT04220658 | / | To evaluate correlations between epigenetic aging and NAD+ levels | Biomarkers of aging including NAD+ levels in whole blood, interleukins, inflammatory cytokines, growth factors, omega-3 polyunsaturated fatty acids, and patterns in DNA methylation will be measured in adults aged 25 to 80 years old | Epigenetics |
NCT05593939 | NR | To investigate whether NR can slow aging in human | Healthy adults older than 65 years will be randomized into either an aerobic exercise, time-restricted feeding, NR (2000 mg/day) or control group and followed for 12 weeks | Aging |
NCT03501433 | NR | To evaluate the effects of NR on metabolism and vascular function | Young (18–35) and older (60–75) adults will take 500 mg NR or placebo daily for 7 days | Aging Lipemia |
NCT03432871 | NR | To investigate the role of NR in mitochondrial biogenesis | Mitochondrial disease patients aged 18 to 70 years will take 10 mg/kg body weight NR daily for 4 weeks | Mitochondrial diseases Mitochondrial myopathies Mitochondrial DNA deletion |
NCT03151239 | NMN | To evaluate the effect of NMN on risk factors for diabetes and cardiovascular disease | Postmenopausal and prediabetes women aged 55 to 75 years will take 250 mg NMN or placebo daily for 8 | Glucose metabolism disorder |
NCT04228640 | NMN | To evaluate the efficacy and safety of Uthever (NMN) | Adults aged 45 to 60 years will take 300 mg NMN or placebo daily for 60 days | Aging |
NCT04823260 | NMN | To evaluate the efficacy and safety of NMN as an anti-aging supplement | Adults aged 40 to 65 years will take 300–900 mg NMN or placebo daily for 60 days | Aging |